Cargando…

CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener

Background: K(ATP) channels have diverse roles, including regulation of insulin secretion and blood flow, and protection against biological stress responses and are excellent therapeutic targets. Different subclasses of K(ATP) channels exist in various tissue types due to the unique assemblies of sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gando, Ivan, Becerra Flores, Manuel, Chen, I.-Shan, Yang, Hua-Qian, Nakamura, Tomoe Y., Cardozo, Timothy J., Coetzee, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319115/
https://www.ncbi.nlm.nih.gov/pubmed/37408765
http://dx.doi.org/10.3389/fphar.2023.1197257
_version_ 1785068176171597824
author Gando, Ivan
Becerra Flores, Manuel
Chen, I.-Shan
Yang, Hua-Qian
Nakamura, Tomoe Y.
Cardozo, Timothy J.
Coetzee, William A.
author_facet Gando, Ivan
Becerra Flores, Manuel
Chen, I.-Shan
Yang, Hua-Qian
Nakamura, Tomoe Y.
Cardozo, Timothy J.
Coetzee, William A.
author_sort Gando, Ivan
collection PubMed
description Background: K(ATP) channels have diverse roles, including regulation of insulin secretion and blood flow, and protection against biological stress responses and are excellent therapeutic targets. Different subclasses of K(ATP) channels exist in various tissue types due to the unique assemblies of specific pore-forming (Kir6.x) and accessory (SURx) subunits. The majority of pharmacological openers and blockers act by binding to SURx and are poorly selective against the various K(ATP) channel subclasses. Methods and Results: We used 3D models of the Kir6.2/SUR homotetramers based on existing cryo-EM structures of channels in both the open and closed states to identify a potential agonist binding pocket in a functionally critical area of the channel. Computational docking screens of this pocket with the Chembridge Core chemical library of 492,000 drug-like compounds yielded 15 top-ranked “hits”, which were tested for activity against K(ATP) channels using patch clamping and thallium (Tl(+)) flux assays with a Kir6.2/SUR2A HEK-293 stable cell line. Several of the compounds increased Tl(+) fluxes. One of them (CL-705G) opened Kir6.2/SUR2A channels with a similar potency as pinacidil (EC(50) of 9 µM and 11 μM, respectively). Remarkably, compound CL-705G had no or minimal effects on other Kir channels, including Kir6.1/SUR2B, Kir2.1, or Kir3.1/Kir3.4 channels, or Na(+) currents of TE671 medulloblastoma cells. CL-705G activated Kir6.2Δ36 in the presence of SUR2A, but not when expressed by itself. CL-705G activated Kir6.2/SUR2A channels even after PIP(2) depletion. The compound has cardioprotective effects in a cellular model of pharmacological preconditioning. It also partially rescued activity of the gating-defective Kir6.2-R301C mutant that is associated with congenital hyperinsulinism. Conclusion: CL-705G is a new Kir6.2 opener with little cross-reactivity with other channels tested, including the structurally similar Kir6.1. This, to our knowledge, is the first Kir-specific channel opener.
format Online
Article
Text
id pubmed-10319115
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103191152023-07-05 CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener Gando, Ivan Becerra Flores, Manuel Chen, I.-Shan Yang, Hua-Qian Nakamura, Tomoe Y. Cardozo, Timothy J. Coetzee, William A. Front Pharmacol Pharmacology Background: K(ATP) channels have diverse roles, including regulation of insulin secretion and blood flow, and protection against biological stress responses and are excellent therapeutic targets. Different subclasses of K(ATP) channels exist in various tissue types due to the unique assemblies of specific pore-forming (Kir6.x) and accessory (SURx) subunits. The majority of pharmacological openers and blockers act by binding to SURx and are poorly selective against the various K(ATP) channel subclasses. Methods and Results: We used 3D models of the Kir6.2/SUR homotetramers based on existing cryo-EM structures of channels in both the open and closed states to identify a potential agonist binding pocket in a functionally critical area of the channel. Computational docking screens of this pocket with the Chembridge Core chemical library of 492,000 drug-like compounds yielded 15 top-ranked “hits”, which were tested for activity against K(ATP) channels using patch clamping and thallium (Tl(+)) flux assays with a Kir6.2/SUR2A HEK-293 stable cell line. Several of the compounds increased Tl(+) fluxes. One of them (CL-705G) opened Kir6.2/SUR2A channels with a similar potency as pinacidil (EC(50) of 9 µM and 11 μM, respectively). Remarkably, compound CL-705G had no or minimal effects on other Kir channels, including Kir6.1/SUR2B, Kir2.1, or Kir3.1/Kir3.4 channels, or Na(+) currents of TE671 medulloblastoma cells. CL-705G activated Kir6.2Δ36 in the presence of SUR2A, but not when expressed by itself. CL-705G activated Kir6.2/SUR2A channels even after PIP(2) depletion. The compound has cardioprotective effects in a cellular model of pharmacological preconditioning. It also partially rescued activity of the gating-defective Kir6.2-R301C mutant that is associated with congenital hyperinsulinism. Conclusion: CL-705G is a new Kir6.2 opener with little cross-reactivity with other channels tested, including the structurally similar Kir6.1. This, to our knowledge, is the first Kir-specific channel opener. Frontiers Media S.A. 2023-06-20 /pmc/articles/PMC10319115/ /pubmed/37408765 http://dx.doi.org/10.3389/fphar.2023.1197257 Text en Copyright © 2023 Gando, Becerra Flores, Chen, Yang, Nakamura, Cardozo and Coetzee. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Gando, Ivan
Becerra Flores, Manuel
Chen, I.-Shan
Yang, Hua-Qian
Nakamura, Tomoe Y.
Cardozo, Timothy J.
Coetzee, William A.
CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener
title CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener
title_full CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener
title_fullStr CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener
title_full_unstemmed CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener
title_short CL-705G: a novel chemical Kir6.2-specific K(ATP) channel opener
title_sort cl-705g: a novel chemical kir6.2-specific k(atp) channel opener
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319115/
https://www.ncbi.nlm.nih.gov/pubmed/37408765
http://dx.doi.org/10.3389/fphar.2023.1197257
work_keys_str_mv AT gandoivan cl705ganovelchemicalkir62specifickatpchannelopener
AT becerrafloresmanuel cl705ganovelchemicalkir62specifickatpchannelopener
AT chenishan cl705ganovelchemicalkir62specifickatpchannelopener
AT yanghuaqian cl705ganovelchemicalkir62specifickatpchannelopener
AT nakamuratomoey cl705ganovelchemicalkir62specifickatpchannelopener
AT cardozotimothyj cl705ganovelchemicalkir62specifickatpchannelopener
AT coetzeewilliama cl705ganovelchemicalkir62specifickatpchannelopener